Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.82 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.46 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.46 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844235 | 0.98 | MET (0.84) | METMAP4K2MAP3K1AAK1Q6ZSR9 | |
| Hydrochloric Acid SCHEMBL2844939 | 0.98 | MET (0.83) | METMAP4K2MAP3K1AAK1Q6ZSR9 | |
| SCHEMBL2846148 | 0.92 | MET (0.74) | METMAP4K2MAP3K1AAK1Q6ZSR9 | |
| SCHEMBL30452784 | 0.90 | MET (1.00) | METMAP4K2MAP3K1AAK1MAP4K5 | |
| SCHEMBL487888 | 0.90 | MET (1.00) | METMAP4K2MAP3K1AAK1MAP4K5 | |
| Hydrochloric Acid SCHEMBL2840128 | 0.87 | MET (0.65) | METMAP4K2MAP3K1AAK1Q6ZSR9 | |
| SCHEMBL13412111 | 0.86 | MET (0.65) | METMAP4K2MAP3K1AAK1Q6ZSR9 | |
| SCHEMBL488118 | 0.85 | MET (0.91) | METMAP4K2MAP3K1AAK1MAP4K5 | |
| SCHEMBL30453588 | 0.85 | MET (0.91) | METMAP4K2MAP3K1AAK1MAP4K5 | |
| SCHEMBL13412110 | 0.85 | MET (0.64) | METMAP4K2MAP3K1AAK1Q6ZSR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2010-03-11 | — | — | US | claimed |
| EP-2120578-A1 | KINASE INHIBITOR COMPOUNDS | Xcovery, INC. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2008088881-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-8551995-B2 | (4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-phenyl)-morpholin-4-yl-methanone; useful in treating disorders related to abnormal protein kinase activities such as cancer | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2120578-A1 | KINASE INHIBITOR COMPOUNDS | Xcovery, INC. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008088881-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | MAP4K2, MAP3K5, MAP3K15 | MET 1412/4885MAP4K2 1/4885MAP3K1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.